GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » LifeMD Inc (NAS:LFMD) » Definitions » ROE %
中文

LifeMD (LifeMD) ROE %

: 0.00% (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. LifeMD's annualized net income for the quarter that ended in Dec. 2023 was $-14.9 Mil. LifeMD's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-4.6 Mil. Therefore, LifeMD's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for LifeMD's ROE % or its related term are showing as below:

LFMD's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 4.11
* Ranked among companies with meaningful ROE % only.

LifeMD ROE % Historical Data

The historical data trend for LifeMD's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -32,047.54 -431.82 -454.88 -

LifeMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Health Information Services subindustry, LifeMD's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeMD ROE % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, LifeMD's ROE % distribution charts can be found below:

* The bar in red indicates where LifeMD's ROE % falls into.



LifeMD ROE % Calculation

LifeMD's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-20.596/( (-6.83+3.505)/ 2 )
=-20.596/-1.6625
=N/A %

LifeMD's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-14.928/( (-12.671+3.505)/ 2 )
=-14.928/-4.583
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


LifeMD  (NAS:LFMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-14.928/-4.583
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.928 / 179.44)*(179.44 / 49.586)*(49.586 / -4.583)
=Net Margin %*Asset Turnover*Equity Multiplier
=-8.32 %*3.6188*N/A
=ROA %*Equity Multiplier
=-30.11 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-14.928/-4.583
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-14.928 / -11.176) * (-11.176 / -8.688) * (-8.688 / 179.44) * (179.44 / 49.586) * (49.586 / -4.583)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.3357 * 1.2864 * -4.84 % * 3.6188 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


LifeMD ROE % Related Terms

Thank you for viewing the detailed overview of LifeMD's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeMD (LifeMD) Business Description

Traded in Other Exchanges
N/A
Address
236 Fifth Avenue, Suite 400, Fourth Floor, New York, NY, USA, 10001
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Executives
Bertrand Velge director BARNHOUSE FARM, BARNHOUSE LANE BROOKLAND, ROMNEY MARSH, KENT X0 TN299TR
William J Febbo director, other: Consultant 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Nicholas P Alvarez officer: Chief Acquisition Officer C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Eric Harold Yecies officer: CCO and General Counsel C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Brad Michael Roberts officer: Chief Operating Officer 300 CHAFFORD COURT, SIMPSONVILLE SC 29681
Justin Schreiber director, 10 percent owner, officer: President, Immudyne PR 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Stefan Galluppi director, officer: Chief Operating Officer C/O LIFEMD, INC, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Joan Larovere director C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Jessica Friedeman officer: Chief Marketing Officer C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Kathleen E Walsh director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Piyush Jindal director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Joseph Ditrolio director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Maria E. Stan officer: Principal Accounting Officer 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Dennis Wijnker officer: Chief Technology Officer 536 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Naveen Bhatia director 823 GREENTREE RD, PACIFIC PALISADES CA 90272